Creative Medical Tech Holdings, Inc. (CELZ) is experiencing an 81% surge in shares on Thursday following the company's announcement of FDA approval for expanded access therapy utilizing CELZ-201, also referred to as ImmCelz.
This cell-based program aims to manage abnormal glucose tolerance and prevent Type 1 Diabetes Mellitus in high-risk individuals.
The FDA granted an Orphan Drug Designation for CELZ-201 the day before.
CELZ is trading on the Nasdaq at $8.64, up 81.51% or $3.88 per share. It has traded between $3.93 and $13.30 in the past 52-week period.
For comments and feedback: editorial@rttnews.com